Donepezil-ferulic acid hybrids as anti-Alzheimer drugs

Future Medicinal Chemistry

Volumn 7, Issue 1, 2015, Pages 15-21

  Benchekroun, Mohamed ^a   Ismaili, Lhassane ^a   Pudlo, Marc ^a   Luzet, Vincent ^a   Gharbi, Tijani ^a   Refouvelet, Bernard ^a   Marco Contelles, José ^b  

^a Centre Hospitalier Universitaire de Besançon   (France)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; DONEPEZIL FERULIC ACID HYBRIDS DERIVATIVE; FERULIC ACID; MELATONIN; N [ 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] 3 (4 HYDROXY 3 METHOXYPHENYL) N [2 [[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]AMINO]2 OXOETHYL]ACRYLAMIDE; NOOTROPIC AGENT; TROLOX C; UNCLASSIFIED DRUG; ANTIOXIDANT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; COUMARIC ACID; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; EQUIDAE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MOTIF; SERUM; CHEMISTRY; HUMAN; METABOLISM; SYNTHESIS;

ALZHEIMER DISEASE; ANTIOXIDANTS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COUMARIC ACIDS; HUMANS; INDANS; PIPERIDINES;

EID: 84921395943     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.148     Document Type: Article

References (31)

1. Seshadri S, Wolf PA, Beiser A. et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 49(6), 1498-1504 (1997
2. Klunk WE. Biological markers of Alzheimer's disease. Neurobiol. Aging 19(2), 145-147 (1998
3. Selkoe D. Alzheimer's disease: genes, proteins, and therapy. J. Physiol. Rev. 81(2), 741-766 (2001
4. Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech. Ageing Dev. 122(16), 1961-1969 (2001
5. Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 33(1), 139-189 (2013
6. Rosini M, Simoni E, Milelli A. et al. Oxidative stress in Alzheimer's disease: are we connecting the dots?. J. Med. Chem. 57(7), 2821-2831 (2014
7. Mangialasche F, Polidori, MC, Monastero R. et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 8(4), 285-305 (2009
8. Esquivias-Perez M, Maalej E, Romero A. et al. Nontoxic and neuroprotective ß-naphthotacrines for Alzheimer's disease. Chem. Res. Toxicol. 26(6), 986-992 (2013
9. Rodriguez-Franco MI, Fernandez-Bachiller MI, Perez C. et al. Novel tacrine-melatonin hybrids as dualacting drugs for Alzheimer's disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49(2), 459-462 (2006
10. Pudlo M, Luzet V, Ismaili L. et al. Quinolone - benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer's disease. Bioorg. Med. Chem. 22(8), 2496-2507 (2014
11. Chen Y, Sun J, Fang L. et al. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl and butyrylcholinesterase inhibitors. J. Med. Chem. 55(9), 4309-4321 (2012
12. Chao X, He X, Yang Y. et al. Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem. Lett. 22(20), 6498-6502 (2012
13. Fang L, Kraus B, Lehmann J. et al. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett. 18(9), 2905-2909 (2008
14. Pi R, Mao X, Chao X. et al. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-ß-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS ONE 7(2), e31921 (2012
15. Fernandez-Bachiller MI, Perez, C, Campillo NR. et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 4(5), 828-841 (2009
16. Zawadzka A, Lozinska I, Moleda Z. et al. Highly selective inhibition of butyrylcholinesterase by a novel melatonin - tacrine heterodimers. J. Pineal Res. 54(4), 435-441 (2013
17. Chojnacki JE, Kai L, Xing Y. et al. Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy- 1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin. ACS Chem. Neurosci. 5(8), 690-699 (2014
18. Kawakami Y, Inoue A, Kawai T. et al. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. 4(9), 1429-1446 (1996
19. Luo Z, Sheng J, Sun Y. et al. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J. Med. Chem. 56(22), 9089-9099 (2013
20. Ismaili L, Nadaradjane A, Nicod L. et al. Synthesis and antioxidant activity evaluation of new hexahydropyrimido[5,4-c]quinoline-2,5-diones and 2-thioxohexahydropyrimido[5,4-c]quinoline-5-ones obtained by Biginelli reaction in two steps. Eur. J. Med. Chem. 43(6), 170-175 (2008
21. Perez-Labrada K, Brouard I, Mendez I. et al. Multicomponent synthesis of Ugi-type ceramide analogues and neoglycolipids from lipidic isocyanides. J. Org. Chem. 77(10), 4660-4670 (2012
22. Samadi A, Chioua M, Bolea I. et al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 46(9), 4665-4668 (2011
23. Davalos A, Gomez-Cordobes C, Bartolome B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J. Agric. Food Chem. 52(1), 48-54 (2004
24. Ellman GL, Courtney KD, Andres V Jr. et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7(2), 88-95 (1961
25. Arendt T, Bruckner MK, Lange M. et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development. A study of molecular forms. Neurochem. Int. 21(3), 381-396 (1992
26. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4(2), 131-138 (2003
27. Greig NH, Utsuki T, Ingram DK. et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer ß-amyloid peptide in rodent. Proc. Natl Acad. Sci. USA 102(47), 17213-17218 (2005
28. Martinez A. Emerging Drug and Targets for Alzheimer's Disease, Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Atrategies (1th Edition). RSC Publishing, Cambridge, UK (2010
29. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev. Neurother. 10(5), 711-728 (2010
30. Romero A, Cacabelos R, Oset-Gasque MJ. et al. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 23(7), 1916-1922 (2013
31. Wang L, Esteban G, Ojima M. et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 80, 543-561 (2014